Bruce Booth, D.Phil.

Bruce serves as a board member to Sionna and is also a partner at Atlas Venture where he focuses on the discovery and development of novel medicines and therapeutic platforms. Currently, Bruce is chair or a member of the board of directors of several private companies, including Nimbus Therapeutics, HotSpot Therapeutics, and Matchpoint Therapeutics.  He also serves on the board of several seed-stage companies including Elephant Bio and Yemaya, Inc.  Bruce has served as an advisor in various capacities to Takeda, UCB and the Gates Foundation. Before joining Atlas in 2005, Bruce was a consultant at McKinsey & Company, as well as an investor for Caxton Health Holdings. Bruce was a British Marshall Scholar and received a D.Phil. in molecular immunology from Oxford University. He received a B.S. in biochemistry, summa cum laude, from The Pennsylvania State University.